More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
An Extraordinary General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 30 November 2017 at 13:00 CET.
Please find the notice including agenda for the Extraordinary General Meeting and appendices attached to this disclosure. The notice will also be sent to all shareholders. The notice and appendices will also be made available on Targovax' website www.targovax.com under Corporate Governance and General Meetings.
Notice of attendance must be received no later than 29 November 2017 at 16:00 CET.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/fcacf98b-f8fb-40f6-b822-191b62ad0730
